Could a heart pill beat long COVID fatigue? new trial aims to find out.

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adult who is 18-50 years old * Confirmed (PCR or serology), non-hospitalized, mild to moderate acute COVID-19 cases according to WHO criteria with proven chronic ED and either: ME/CFS Canadian Consensus Criteria (CCC) with post exertional malaise (PEM) 2 - 14 hours = PCS or ME/CFS CCC criteria with PEM \> 14 hours = PCS/CFS * Ongoing symptoms of PCS or PCS/CFS for ≥ 6 months * Bell Score: 30-60 * Evidence for endothelial dysfunction (ED) \[as indicated by reactive hyperemia index (RHI) \< 1.8 and/or ET-1 level \> 90 percentile of healthy age- and gender matched controls or muscle fatigue (below cut-off values of area under the curve reference values for age-matched healthy controls and/or pathological optical coherence tomography angiography (OCTA))\] * For female subjects: Confirmed post-menopausal state (defined as amenorrhea for at least 12 months) or for women of childbearing potential: Negative highly sensitive urine or serum pregnancy test before inclusion/randomisation and practicing a highly effective birth control method (failure rate of less than 1 %): * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral/intravaginal/transdermal), or * progestogen-only hormonal contraception associated with inhibition of ovulation (oral/injectable/implantable), or * intrauterine device, or * intrauterine hormone-releasing system, or * bilateral tubal occlusion, or * vasectomised partner, or * heterosexual abstinence. Exclusion Criteria: * COVID-19 vaccination within the last 4 weeks before inclusion * Pre-COVID history of chronic fatigue syndrome or other fatigue syndromes that are due to associated diseases (e.g., cancer, autoimmune diseases \[patients with a preexisting Hashimoto thyroiditis and/or fibromyalgia without fatigue syndromes can be included\]) * Concomitant use of Vericiguat due to other diseases * Contraindications against IMP * Concurrent or anticipated concomitant use of PDE-5 inhibitors such as vardenafil, tadalafil, and sildenafil, nitrates, or sGC-stimulators * Use of other sGC stimulators, e.g., riociguat * Hypersensitivity to the active substance or any of the other ingredients * Systolic blood pressure: \< 100 mmHg at screening * Known SARS-CoV-2 infection-related organ damage/comorbidity * Severe renal or hepatic insufficiency * Pregnancy or breastfeeding